Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$36.16 USD
-0.42 (-1.15%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $36.13 -0.03 (-0.08%) 7:44 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Cytokinetics, Incorporated's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CYTK 36.16 -0.42(-1.15%)
Will CYTK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYTK
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Other News for CYTK
Cytokinetics (CYTK) Downgraded Amid Potential Challenges
Cytokinetics Merits A Speculative Buy Rating
Cytokinetics Inc (CYTK) Announces Upcoming Q2 2025 Financial Results and Conference Call | CYTK ...
Cytokinetics to Announce Second Quarter Results On August 7, 2025 | CYTK Stock News
Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK)